Healing of the bone with anti-fracture drugs

Bibliography

• Einhorn TA, Laurencin CT, Lyons K. Fracture repair: challenges, opportunities, and directions for future research. J Bone Joint Surg Am 2008;90:438-42
   PubMedGoogle Scholar
• Corrales LA, Morshed S, Bhandari M, Miclau T III. Variability in the assessment of fracture–healing in orthopaedic trauma studies. J Bone Joint Surg Am 2008;90:1862-88
   PubMedGoogle Scholar
• Goldhahn J, Mitlak BH, Aspenberg P, et al. Critical issues in translational and clinical research fort he study of new technologies to enhance bone repair. J Bone Joint Surg Am 2008;90:43-7
   PubMedGoogle Scholar
• Goldhahn J, Scheele WH, Mitlak BH, et al. Clinical evaluation of medicinal products for acceleration of fracture healing in patient with osteoporosis. Bone 2008;43:343-7
   PubMed Web of Science ®Google Scholar
• Goldhahn J, Beaton D, Ladd A, et al. Recommendation for measuring clinical outcome in distal radius fractures – a core set of domains for standardized reporting in clinical practice and research. In press
   Google Scholar
• Dimitriou R, Jones E, McGonagle D, Giannoudis PV. Bone regeneration: current concepts and future directions. BMC Med 2011;9:66-75
   PubMed Web of Science ®Google Scholar
• Cox G, Einhorn TA, Tzioupis C, Giannoudis PV. Bone turnover markers in fracture healing. J Bone Joint Surg Br 2010;92:B329-34
   PubMedGoogle Scholar
• Lecart MP, Reginster JY. Current options for the management of postmenopausal osteoporosis. Expert Opin Pharmacother 2011;12:2533-52
   PubMed Web of Science ®Google Scholar
• Aspenberg P. Drugs and fracture repair. Acta Orthop 2005;76:741-8
   PubMed Web of Science ®Google Scholar
• Bukata SV. Systemic administration of pharmacological agents and bone repair:what can we expect. Injury 2011;42:605-8
   PubMed Web of Science ®Google Scholar
• Jorgensen NR, Schwarz P. Effects of anti–osteoporosis medications on fracture healing. Curr Osteoporos Rep 2011;9:149-55
   PubMedGoogle Scholar
• Einhorn TA. Can anti–fracture agents heal fractures? Cln Cases Miner Bone Metab 2010;7:11-14
   PubMedGoogle Scholar
• Goldhahn J, Féron JM, Kanis J, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 2012;90:343-53
   PubMed Web of Science ®Google Scholar
• Brandi ML. Drugs and bone healing. Expert Opin Investig Drugs 2012;1:1169-76
   Google Scholar
• Wase AW, Solewski J, Rickes E, Seidenberg J. Action of thyrocalcitonin on bone. Nature 1967;214:388-9
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Silverman S, Adriano K, et al. A randomized trial of nasal salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76
   PubMed Web of Science ®Google Scholar
• Paavolainen P, Taivainen T, Michelsson JE, et al. Calcitonin and fracture healing. An experimental study on rats. J Orthop Res 1989;7:100-6
   PubMed Web of Science ®Google Scholar
• Schatzker J, Chapman M, HàEri GB, et al. The effect of calcitonin on fracture healing. Clin Orthop 1979;141:303-6
   Google Scholar
• Meller Y, Shaikin–Kestenbaum R, Shany S, et al. Parathyroid hormone, calcitonin, and vitamin D metabolites during normal fracture healing in humans. Clin Orthop 1984;183:238-45
   Google Scholar
• Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol 2011;8:81-91
   PubMed Web of Science ®Google Scholar
• Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97:2692-6
   PubMed Web of Science ®Google Scholar
• Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94
   PubMed Web of Science ®Google Scholar
• Dempster DW. Exploiting and bypassing the bone remodelling cycle to optimize treatment of osteoporosis. J Bone Miner Res 1997;12:1152-4
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363-73
   PubMed Web of Science ®Google Scholar
• Im GI, Qureshi A, Kenney J, et al. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004;25:4105-15
   PubMed Web of Science ®Google Scholar
• Follet H, Li J, Phipps RJ, et al. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 2007;40:1172-7
   PubMedGoogle Scholar
• Plotkin LI, Lezcano V, Thostenon J, et al. Connexin 43 is required for the antiapoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008;23:1712-21
   PubMed Web of Science ®Google Scholar
• Naidu A, Dechow PC, Spears R, et al. The effect of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:5-13
   PubMedGoogle Scholar
• Goodship E, Walker PC, McNally D, et al. Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 1994;5:S53-5
   Google Scholar
• Peter CP, Cook WO, Nunamaker DM, et al. Effect of alendronate on fracture healing and bone remodelling in dogs. J Orthop Res 1996;14:74-9
   PubMed Web of Science ®Google Scholar
• Li J, Mori S, Kaji Y, et al. Concentration of bisphosphonate (icandronate) in callus area and its effectson fracture healing in rats. J Bone Miner Res 2000;15:2042-51
   PubMed Web of Science ®Google Scholar
• Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture reèair differently in ovariectomzed rats. J Bone Miner Res 2002;17:2237-46
   PubMed Web of Science ®Google Scholar
• Bauss F, Schenk RK, Hort S, et al. New model for simulation of fracture repair in full–grown beagle dogs: model characterization and results from a long–term study with ibandronate. J Pharmacol Toxicol Methods 2004;50:25-34
   PubMedGoogle Scholar
• Amanat N, McDonald M, Godfrey C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 2007;22:867-76
   PubMed Web of Science ®Google Scholar
• Amanata N, He LH, Swain MV, Little DG. The effect of zoledronic acid on the intrinsic material properties of healing bone: an indentation study. Med Eng Phys 2008;30:843-7
   PubMedGoogle Scholar
• Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009;24:196-208
   PubMed Web of Science ®Google Scholar
• Yu YY, Lieu S, Hu D, et al. Site specific effects of zoledronic acid during tibial and mandibular fracture repair. PLoS One 2012;7:e31771
   Google Scholar
• Matos MA, Tannuri U, Guarniero R. The effect of zoledronate during bone healing. J Orthop Traumatol 2010;11:7-12
   PubMedGoogle Scholar
• Kinov P, Tivchev P, Doukova P, Leithner A. Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomized study. Arch Orthop Belg 2006;72:44-50
   PubMedGoogle Scholar
• Hilding M, Aspenberg P. Local preoperative treatment with bisphosphonate improves the fixation of total knee prostheses. Arch Orthoped 2007;78:795-9
   Google Scholar
• Solomon HMC, Mogun H, Schneeweiss S. The relation between bisphosphonate use and non–union of fractures of the humerus in oldr adults. Osteoporos Int 2009;20:895-901
   PubMed Web of Science ®Google Scholar
• Moroni A, Faldini C, Hoang–Kim A, et al. Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am 2007;89:96-101
   PubMed Web of Science ®Google Scholar
• Rozental TD, Vasquez MA, Chacko AT, et al. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate theraèy. J Hand Surg Am 2009;34:595-602
   PubMed Web of Science ®Google Scholar
• Colon–Emeric C, Nordsletten L, Olson S, et al. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 2010;22:2329-36
   PubMed Web of Science ®Google Scholar
• Harding AK, W–Dahl A, Geijer M, et al. A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies. Acta Orthop 2011;82:465-70
   PubMed Web of Science ®Google Scholar
• Stuermer EK, Sehmisch S, Rack T, et al. Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture–healing model at the tibia in the rat. Langenbecks Arch Surg 2010;395:163-72
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
   PubMed Web of Science ®Google Scholar
• Kamiya N. The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Curr Mol Pharmacol 2012;5:153-63
   PubMedGoogle Scholar
• Alkhiari YM, Gerstenfeld LC, Krall E, et al. Enhancement of experimental fracture–healing by systemic administration of recombinant human parathyroid hormone (PTH 1–34). J Bone Joint Surg Am 2005;87:731-41
   PubMedGoogle Scholar
• Raghavan P, Christofides E. Role of teriparatide in accelerating metatarsal stress fracture healing: a case series and review of literature. Clin Med Insights Endocrinol Diabetes 2012;5:39-45
   PubMedGoogle Scholar
• Peichl P, Holzer LA, Maier R, Olzer G. Parathyroid hormone 1–84 accelerates fracture–healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 2011;93:1583-7
   PubMed Web of Science ®Google Scholar
• Aspenberg P, Genant HK, Johansson T, et al. Teriparatide fort he acceleration of fracture repair in humans: a prospective, randomized, double–blind study for 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010;25:404-14
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
   PubMed Web of Science ®Google Scholar
• Habermann B, Kafchitsas K, Olender G, et al. Strontium ranelate enhances callus strength more than PTH 1–34 in an osteoporotic model of fracture healing. Calcif Tissue Int 2010;86:82-9
   PubMed Web of Science ®Google Scholar
• Frost HM. A Brief review for orthopaedic surgeons: fatigue damage (microdamage) in bone (its determinants and clinical implications). J Orthop Sci 1998;3:272-81
   PubMedGoogle Scholar
• Hashimoto T, Shigetomi M, Ohno T, et al. Sequential treatment with intermittent low–dose human parathyroid hormone (1–34) and bisphosphonate enhances large–size skeletal reconstruction by valcularized bone transplantation. Calcif Tissue Int 2007;81:232-9
   PubMedGoogle Scholar
• Aspenberg P, Wermelin K, Tengwall P, Fahlgren A. Additive effects of PTH and bisphosphonates on the bone healing response to metaphyseal implants in rats. Acta Orthop 2008;79:111-15
   PubMed Web of Science ®Google Scholar
• Birke O, Schindeler A, Ramachandran M, et al. Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphophonates in the treatment of congenital pseudoarthrosis of the tibia. J Child Orthop 2010;4:507-17
   PubMedGoogle Scholar
• Doi Y, Miyazaki M, Yoshiiwa T, et al. Manipulation of the anabolic and catabolic responses with BMP–2 and zoledronic acid in a rat femoral fracture model. Bone 2011;49:777-82
   PubMed Web of Science ®Google Scholar
• Larsson S, Fazzolari NL. Anti–osteoporosis therapy and fracture healing. Arch Orthop Trauma Surg 2012; Epub ahead of print
   PubMedGoogle Scholar
• Yu NY, Schindeler A, Tagil M, et al. Application of BMPs and bisphosphonates in improving bone fracture healing. Front Biosci 2012;4:2647-53
   Google Scholar
• Li HF, Zhou CC, Li JH, et al. The effects of combined human parathyroid hormone 81–349 and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int 2012;23:1463-74
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezikian JP, Ensrud KE, et al. PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 2005;353:555-65
   PubMed Web of Science ®Google Scholar